<code id='51C3D15C30'></code><style id='51C3D15C30'></style>
    • <acronym id='51C3D15C30'></acronym>
      <center id='51C3D15C30'><center id='51C3D15C30'><tfoot id='51C3D15C30'></tfoot></center><abbr id='51C3D15C30'><dir id='51C3D15C30'><tfoot id='51C3D15C30'></tfoot><noframes id='51C3D15C30'>

    • <optgroup id='51C3D15C30'><strike id='51C3D15C30'><sup id='51C3D15C30'></sup></strike><code id='51C3D15C30'></code></optgroup>
        1. <b id='51C3D15C30'><label id='51C3D15C30'><select id='51C3D15C30'><dt id='51C3D15C30'><span id='51C3D15C30'></span></dt></select></label></b><u id='51C3D15C30'></u>
          <i id='51C3D15C30'><strike id='51C3D15C30'><tt id='51C3D15C30'><pre id='51C3D15C30'></pre></tt></strike></i>

          Home / explore / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:8

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In